Neurocrine CEO Kevin Gorman to retire after 32-year run; Bluebird picks up fifth CFO in three years

After more than three decades at Neurocrine, CEO Kevin Gorman will retire later this year, handing the reins of the $13 billion neuroscience drugmaker over …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Vampiric cancer cells, a brain atlas, & alleged misconduct at Cassava

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Hello! Today, we learn

October 13, 2023

AbbVie concludes acquisition of ImmunoGen for $10.1bn

Share this article ImmunoGen’s pipeline complements the existing oncology portfolio of AbbVie. Credit: JHVEPhoto / Shutterstock.com. AbbVie has completed the acquisition of ImmunoGen for $10.1bn,

February 13, 2024

CrowdStrike outage hits US hospitals

CrowdStrike, a growing cybersecurity firm, unwittingly triggered a massive IT outage on Friday, disrupting businesses, including healthcare, after issuing what was supposed to be a routine software

July 19, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.